Quantum BioPharma Receives FDA Clearance to Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis
NASDAQ: QNTM | CSE: QNTM | FRA: 0K91 Overview Quantum BioPharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), enabling the company to advance its patented, first-in-class multiple sclerosis program